ABL Diagnostics announces the payment of its first dividend for the 2024 financial year

June 26, 2025 02:12 AM AEST | By EIN Presswire

Google News:

ABL Diagnostics announces the payment of its first dividend for the 2024 financial year — Image source: EIN Presswire

Recent News

Renforth Appoints New Exploration Leader to Drive Parbec Gold Project

Starcore Reviews El Creston Molybdenum Asset Strategy Amid Mexico Expa...

Queensland Cuts CEI as Copper Ambitions Rise Beyond Coal on All Ordina...

Li-S Energy Advances Defence Battery Strategy with New Partnership | A...

ABL Diagnostics announces its first dividend for 2024 since the 2022 merger that led activity in the field of genotyping diagnostics of infectious diseases

ABL Diagnostics SA (ENX:ABLD)

First dividend for 2024 financial year since the 2022 merger that led ABL Diagnostics' activity in the field of genotyping diagnostics of infectious diseases”

— Dr Chalom B. Sayada

WOIPPY, MOSELLE, FRANCE, June 25, 2025 /EINPresswire.com/ -- The Shareholders' Meeting of ABL Diagnostics, held on Tuesday, June 24, 2025 at 11 a.m., approved all the resolutions submitted to its vote, and in particular the payment of a dividend of €0.05 per share for the 2024 financial year, i.e. a total distribution of €805,732.80 (based on the total number of shares forming the share capital, i.e. 16,114,656 shares, which will, if necessary, be adjusted downwards to take into account the shares deprived of dividend rights (treasury shares) on the ex-dividend date.

The amount of the unit dividend to be paid to these shares will be allocated to the item "Carry forward again".

The ex-dividend date will be June 27, 2025 and the dividend will be paid on July 1, 2025, exclusively in cash.

The voting results for each resolution will be available on the Company's website no later than July 9, 2025.

*****

About ABL Diagnostics
ABL Diagnostics specializes in proprietary molecular biology assays and end-to-end solutions for precise molecular detection and genotyping:
- UltraGene – real-time PCR-based molecular detection.
- DeepChek^® – DNA sequencing for genotyping.

Expanding Portfolio for Microbiology
Our growing portfolio covers:
- HIV diagnostics – Drug resistance assays, including a Whole Genome Kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B & C – Advanced genotyping and drug resistance analysis
- Microbiome & Taxonomy – 16s/18s RNA-based analysis.
- Other viral & bacterial targets – Comprehensive molecular assays.

Syndromic & Digital Solutions
- Syndromic Real-Time PCR assays (known-how and IP acquired in 2025).
- Nadis^® – EMR system used in 200+ hospitals in France for HIV & Hepatitis infected patients management.
ABL DIAGNOSTICS is listed on the Euronext Compartment B market of NYSE EURONEXT - ISIN code: FR001400AHX6

Dr Sayada
ABL Diagnostics SA
+33 7 83 64 68 50
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

RBAC Welcomes New Board Chair and Four Distinguished Members
26, June, 2025
3M Young Scientist Challenge Announces 2025 National Finalists
26, June, 2025
Marathon Petroleum Recognized for Excellence in Fleet Safety and Performance
26, June, 2025
Meet Megan McKray: A Champion for Working Parents and Caregivers
26, June, 2025
SLB OneSubsea Secures EPC Contract for Northern Lights CO2 Transport and Storage Project Expansion
26, June, 2025
Awakened Hearts Becomes #1 Amazon Bestseller in Three Spirituality Categories
26, June, 2025
Did You Know Solar Projects May Qualify for a 30% - 50% Tax Credit?
26, June, 2025
Global Logistics Market Outlook: Powering Global Trade to USD 20.1 Trillion by 2033 (7.3% CAGR) | AMR
26, June, 2025
Philips SpeechLive and Actionstep announce partnership to boost law firm productivity
26, June, 2025
Thailand’s Bold Play at THECA 2025 to Become Asia’s Next Electronics Powerhouse
26, June, 2025

View All

Markets

Related Articles

Sponsored Articles

1

2

3

4

5

Investing Ideas

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27